Table 1.
Clinical and demographic characteristics of participants
| Variable | HIV- (n = 14) | IR (n = 18) | INR (n = 18) | p value |
|---|---|---|---|---|
| Age, years, median (IQR) | 33 (31.0–44.0) | 39 (35.0–42.0) | 44 (38.0–46.0) | 0.089a |
| Male gender, N (%) | 9 (64.3%) | 13 (72.2%) | 18 (100%) | < 0.05b |
| BMI, kg/m2; median (IQR) | 26.1 (25.1–27.7) | 23.6 (21.7–26.9) | 22.5 (20.8–24.6) | < 0.01a |
| CD4+ T-cell count, cells/μL; median (IQR) | – | 558.5 (492.0–705.0) | 168 (141.0–256.0) | < 0.001c |
| Nadir CD4+ T-cell count, cells/μL; median (IQR) | - | 69 (25–363.0) | 42 (16.0–72.0) | 0.055c |
| Nadir CD4+ T-cell count, cells/μL; mode | - | 58 | 14 | < 0.01b |
| CD8+ T-cell count, cells/μL; median (IQR) | – | 703.5 (619.0–950.0) | 683.5 (588.0–1000.0) | 0.899c |
| CD4+/CD8+ ratio; median (IQR) | – | 0.8 (0.6–1.1) | 0.21 (0.2–0.4) | < 0.001c |
| Duration of HIV infection, years; median (IQR) | – | 5.7 (3.3–10.0) | 3.28 (1.1–6.9) | 0.066c |
| Duration of ART, years; median (IQR) | – | 5.5 (2.9–9.39) | 2.8 (1.1–6.6) | < 0.05c |
aKruskall-Wallis test with Bonferroni correction, bChi square; cMann-Whitney U test